source
- Astellas secures exclusive option on Audax Biosciences preclinical IL-12 cancer drugAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Audax Biosciences, an Australian biotech company. The asset is an IL-12 based cancer therapeutic that is…
- HHS pauses enforcement of ban on compounding wellness peptides as FDA drafts new rulesHHS announced it will temporarily stop enforcing the existing prohibition on the compounding of certain peptides marketed for wellness. The agency said the move is intended to protect consumer saf…